Kenvue Inc. (KVUE)

NYSE: KVUE · Real-Time Price · USD
15.00
-0.09 (-0.60%)
At close: Oct 24, 2025, 4:00 PM EDT
15.02
+0.02 (0.13%)
After-hours: Oct 24, 2025, 7:59 PM EDT
-0.60%
Market Cap28.79B
Revenue (ttm)15.14B
Net Income (ttm)1.42B
Shares Out 1.92B
EPS (ttm)0.74
PE Ratio20.27
Forward PE14.12
Dividend$0.83 (5.53%)
Ex-Dividend DateAug 13, 2025
Volume20,451,345
Open15.24
Previous Close15.09
Day's Range14.98 - 15.33
52-Week Range14.05 - 25.17
Beta0.67
AnalystsBuy
Price Target20.92 (+39.47%)
Earnings DateNov 7, 2025

About KVUE

Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee’s, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. Its Skin Health and Beauty segment provides face and body care, hair, sun, and other... [Read more]

IPO Date May 4, 2023
Employees 22,000
Stock Exchange NYSE
Ticker Symbol KVUE
Full Company Profile

Financial Performance

In 2024, Kenvue's revenue was $15.46 billion, an increase of 0.07% compared to the previous year's $15.44 billion. Earnings were $1.03 billion, a decrease of -38.10%.

Financial Statements

Analyst Summary

According to 12 analysts, the average rating for KVUE stock is "Buy." The 12-month stock price target is $20.92, which is an increase of 39.47% from the latest price.

Price Target
$20.92
(39.47% upside)
Analyst Consensus: Buy
Stock Forecasts

News

US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On

Five small IPOs debuted and four SPACs listed this week as the government shutdown continues to complicate listings. Two sizable IPOs are scheduled for the week ahead, both of which launched after the...

8 hours ago - Seeking Alpha

Starboard Value CEO: We're thrilled to own Kenvue at this valuation

Starboard Value CEO Jeff Smith joins CNBC's David Faber from 13D Monitor's Active-Passive Investor Summit.

4 days ago - CNBC Television

Kenvue Urges FDA to Reject Request for Autism Warning on Tylenol

Kenvue urged the Food and Drug Administration to deny a proposal to add further warnings to acetaminophen products after the Trump Administration linked Tylenol use during pregnancy to autism.

5 days ago - WSJ

Kenvue urges US FDA to deny request for Tylenol's autism warning

Kenvue has urged U.S. regulators to reject a request for a warning of autism on its popular over-the-counter pain medication Tylenol for use during pregnancy, according to a petition.

5 days ago - Reuters

September Readers ID'd 17 Ideal 'Safer' Dividends In 39 Dogs

This article highlights top ReFa/Ro dividend stocks for September 2025, focusing on high yield and analyst-projected returns through September 2026. MFA Financial, Hafnia, and Energy Transfer lead the...

Other symbols: AAPLAMCRCAGCIMDOWEPDET
7 days ago - Seeking Alpha

Top Stock Movers Now: Oracle, Newmont, Kenvue, American Express, and More

Major U.S. equities indexes climbed at midday Friday as regional bank stocks rebounded from yesterday's losses after a flurry of corporate earnings reports. The Dow, S&P 500, and Nasdaq were all highe...

Other symbols: AXPNEM
8 days ago - Investopedia

Kenvue: A Rock Solid 5% Yield

Kenvue offers stable financials, a robust 5% dividend yield, and the stock trades at a significant discount to peers and historical averages. KVUE's recent decline, driven by Tylenol-related headlines...

10 days ago - Seeking Alpha

Albert Invent Partners with Kenvue to Build the Future of Consumer Health Products With the Help of AI

SUMMIT, N.J. & OAKLAND, Calif.--(BUSINESS WIRE)--Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products like Zyrtec®...

11 days ago - Business Wire

Trump's Tylenol claims limit M&A options for parent company Kenvue

Tylenol maker Kenvue was already having a painful year before U.S. President Donald Trump and his health secretary got involved.

11 days ago - Reuters

Buy Any Of 14 IDEAL 'Safer' S&P 500 October Dividend Dogs

Fourteen of the highest-yielding, 'safer' S&P 500 dividend stocks are currently attractively priced, with free cash flow supporting their payouts. Top ten S&P 500 dividend 'dogs' are projected to deli...

Other symbols: AESAMCRAREBMYCAGCPBDOC
13 days ago - Seeking Alpha

Buy 2 Ideal Dividend Kings Of 25 'Safer' In October's 56

This October's Dividend Kings list features 56 stocks, with Kenvue and United Bankshares meeting the ideal "fair price" yield criteria. Analysts project the top-ten Dividend Kings could deliver 19.2% ...

Other symbols: UBSI
15 days ago - Seeking Alpha

US Republicans and Democrats split on party lines on Trump's Tylenol-autism claim, KFF poll finds

Republicans and Democrats are divided along party lines as to whether they believe the U.S. government's claim that women who take Tylenol during pregnancy are raising the risk of autism in their unbo...

16 days ago - Reuters

Does Tylenol cause autism? Researchers can use ‘natural experiments' to study the link, write Drs.

In the absence of randomized trials on the effects of acetaminophen, researchers need to use ‘natural experiments' to develop better guidance for patients.

22 days ago - WSJ

Kenvue: Trump-Era Volatility Presents A More Attractive Opportunity, But Headwinds Remain

Kenvue faces near-term headwinds from Tylenol-autism allegations, macro uncertainty, and segment underperformance, but offers long-term income potential. Recent leadership changes and a focus on core ...

4 weeks ago - Seeking Alpha

The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.

The CEO behind Tylenol thought he'd found a way to work with the Trump administration. Then everything went off the rails.

4 weeks ago - WSJ

Trump repeats Tylenol and vaccine claims, defying medical community outcry

U.S. President Donald Trump on Friday repeated his call for pregnant women and young children to stop using popular pain medication Tylenol, defying widespread criticism from medical groups, and offer...

4 weeks ago - Reuters

51 September S&P Hi-Yield Aristocrats: 5 To Buy

The article highlights the top ten S&P Hi-Yield Aristocrats for September, with nine stocks offering attractive yields and fair pricing for dividend investors. Analyst forecasts project potential net ...

Other symbols: AMCRAVABENEIXFLOHRLKO
4 weeks ago - Seeking Alpha

RFK Jr. Is Targeting Vaccines And Tylenol. Are Prozac And Ozempic Next?

Tylenol may be only the beginning.

4 weeks ago - Forbes

Attorneys urge court overseeing Tylenol autism lawsuits to consider Trump administration's stance

Families appealing the dismissal of their lawsuits alleging that Kenvue's Tylenol or generic versions of the pain-relief medication caused their children's autism are asking an appeals court to consid...

4 weeks ago - Reuters

RFK Jr.'s team wanted to tout an autism therapy. But a meeting with Tylenol's maker convinced the U.S. health secretary to put the emphasis on acetaminophen

The heads of key health agencies advocated for putting the emphasis on leucovorin, but Kennedy became convinced that he had a moral duty to get the word out about the risk of acetaminophen.

4 weeks ago - WSJ

Kenvue: This Too Shall Pass

Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity. The market reaction appears to be an overreaction, as Tylenol accounts fo...

4 weeks ago - Seeking Alpha

Trump links autism to Tylenol ingredient use during pregnancy — here's what to know

The Trump administration on Monday drew an unproven link between autism and pregnant women's use of acetaminophen, the active ingredient in one of the world's most common over-the-counter pain relieve...

4 weeks ago - CNBC Television

Tylenol maker Kenvue rebounds after Trump spreads unproven claims

Shares of Tylenol maker Kenvue bounced back sharply at the opening bell Tuesday, a day after President Donald Trump promoted unproven and, in some cases, discredited ties between Tylenol, vaccines, an...

4 weeks ago - Fast Company

Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism

Kenvue stock is rebounding. It may be a largely a case of things-could've-been- worse.

4 weeks ago - Investopedia

How Trump is spreading unproven information about Tylenol, autism, and vaccines

President Donald Trump on Monday used the platform of the presidency to promote unproven and in some cases discredited ties between Tylenol, vaccines and autism as his administration announced a wide-...

4 weeks ago - Fast Company